Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for levetiracetam (compound)

Name: etiracetam, S-isomer
Name (isomeric): DB01202
Drug Type: small molecule
Levetiracetamum [INN-Latin]; Levitiracetam; Levetiracetam [INN]
Brand: Keppra
Category: Nootropic Agents, Anticonvulsants
CAS number: 102767-28-2
Indication: Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
Mechanism of Action:
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only mi...
show more »
Absorption: Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
Protein binding: Very low (<10%)
Biotransformation: The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected.
Route of elimination: Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
Half Life: 6-8 hours
Clearance: 0.96 mL/min/kg
Toxicity: Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing
Affected organisms: Humans and other mammals
Food interaction:
Take without regard to meals. Food does not affect bioavailabilty.
Drug interaction:
CarbamazepineConcomitant therapy may results in additive adverse CNS effects.
TriprolidineThe CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.